SIU School of Medicine

Jump directly to a section:

PSOR-010

IRB Number

12-621

ClinicalTrials.gov Identifier

NCT01690299

Trial Status

Open for Enrollment
Phase 3

Why is this study being done?

The purpose of this study is to test apremilast and compare its effects to placebo. The study will also test etanercept, a drug approved to treat psoriasis, and compare its effects to placebo.

Who is eligible to participate?

Adults 18 years old and older who have been diagnosed with psoriasis.

What is involved?

Participants will have a physical examination, physician assessments, and will be asked to complete questionnaires. Urine and blood samples will also be taken. Participants will receive a weekly injection and a pill to be taken twice a day for the first 16 weeks of the study. During this time, participants may receive a placebo pill, a placebo injection, or both. After that, participants will only receive a pill (active medication) to be taken during the rest of the study.

How long is the study?

The study lasts for a period of up to 112 weeks or approximately 2 years.

Who can I contact for additional information?

Please contact Lori Miedwig, CCRP, at (217) 545-4402 or email lmiedwig@siumed.edu

Who is the Principal Investigator of this study?

Stephen Stone, MD

Where is the trial located?

Springfield, Illinois